Logo image of CME

CME GROUP INC (CME) Stock Fundamental Analysis

NASDAQ:CME - Nasdaq - US12572Q1058 - Common Stock - Currency: USD

277.82  +0.29 (+0.1%)

After market: 277.82 0 (0%)

Fundamental Rating

5

CME gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 233 industry peers in the Capital Markets industry. While CME has a great profitability rating, there are some minor concerns on its financial health. CME is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year CME was profitable.
In the past year CME had a positive cash flow from operations.
In the past 5 years CME has always been profitable.
In the past 5 years CME always reported a positive cash flow from operatings.
CME Yearly Net Income VS EBIT VS OCF VS FCFCME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

1.2 Ratios

CME has a Return On Assets of 2.27%. This is comparable to the rest of the industry: CME outperforms 47.64% of its industry peers.
Looking at the Return On Equity, with a value of 13.25%, CME is in the better half of the industry, outperforming 73.39% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 17.02%, CME belongs to the top of the industry, outperforming 92.27% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CME is significantly above the industry average of 7.86%.
The last Return On Invested Capital (17.02%) for CME is above the 3 year average (15.81%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.27%
ROE 13.25%
ROIC 17.02%
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
CME Yearly ROA, ROE, ROICCME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

With a decent Profit Margin value of 35.16%, CME is doing good in the industry, outperforming 79.83% of the companies in the same industry.
CME's Profit Margin has declined in the last couple of years.
CME has a Operating Margin of 78.35%. This is amongst the best in the industry. CME outperforms 99.14% of its industry peers.
CME's Operating Margin has improved in the last couple of years.
Industry RankSector Rank
OM 78.35%
PM (TTM) 35.16%
GM N/A
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
CME Yearly Profit, Operating, Gross MarginsCME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80 100

More info and screens

5

2. Health

2.1 Basic Checks

CME has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, CME has more shares outstanding
CME has a better debt/assets ratio than last year.
CME Yearly Shares OutstandingCME Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
CME Yearly Total Debt VS Total AssetsCME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

Based on the Altman-Z score of 0.75, we must say that CME is in the distress zone and has some risk of bankruptcy.
CME's Altman-Z score of 0.75 is in line compared to the rest of the industry. CME outperforms 44.21% of its industry peers.
CME has a debt to FCF ratio of 0.91. This is a very positive value and a sign of high solvency as it would only need 0.91 years to pay back of all of its debts.
CME has a better Debt to FCF ratio (0.91) than 88.84% of its industry peers.
A Debt/Equity ratio of 0.13 indicates that CME is not too dependend on debt financing.
CME has a better Debt to Equity ratio (0.13) than 79.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 0.91
Altman-Z 0.75
ROIC/WACCN/A
WACCN/A
CME Yearly LT Debt VS Equity VS FCFCME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.3 Liquidity

A Current Ratio of 1.02 indicates that CME should not have too much problems paying its short term obligations.
CME has a Current ratio of 1.02. This is comparable to the rest of the industry: CME outperforms 43.35% of its industry peers.
A Quick Ratio of 1.02 indicates that CME should not have too much problems paying its short term obligations.
CME has a Quick ratio of 1.02. This is comparable to the rest of the industry: CME outperforms 47.64% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
CME Yearly Current Assets VS Current LiabilitesCME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.10% over the past year.
CME shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.57% yearly.
Looking at the last year, CME shows a decrease in Revenue. The Revenue has decreased by -4.04% in the last year.
CME shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.14% yearly.
EPS 1Y (TTM)12.1%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%12%
Revenue 1Y (TTM)-4.04%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%10.38%

3.2 Future

Based on estimates for the next years, CME will show a small growth in Earnings Per Share. The EPS will grow by 7.08% on average per year.
CME is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.32% yearly.
EPS Next Y9.8%
EPS Next 2Y6.97%
EPS Next 3Y7.22%
EPS Next 5Y7.08%
Revenue Next Year7.77%
Revenue Next 2Y5.91%
Revenue Next 3Y5.91%
Revenue Next 5Y4.32%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CME Yearly Revenue VS EstimatesCME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2B 4B 6B 8B 10B
CME Yearly EPS VS EstimatesCME Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 5 10

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 26.31, which means the current valuation is very expensive for CME.
64.81% of the companies in the same industry are cheaper than CME, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.48, CME is valued at the same level.
Based on the Price/Forward Earnings ratio of 23.66, the valuation of CME can be described as rather expensive.
Based on the Price/Forward Earnings ratio, CME is valued a bit more expensive than 62.66% of the companies in the same industry.
CME's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 36.52.
Industry RankSector Rank
PE 26.31
Fwd PE 23.66
CME Price Earnings VS Forward Price EarningsCME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CME indicates a rather cheap valuation: CME is cheaper than 85.84% of the companies listed in the same industry.
CME's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 26.17
EV/EBITDA 12.25
CME Per share dataCME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CME does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of CME may justify a higher PE ratio.
PEG (NY)2.69
PEG (5Y)3.07
EPS Next 2Y6.97%
EPS Next 3Y7.22%

More info and screens

5

5. Dividend

5.1 Amount

CME has a Yearly Dividend Yield of 3.85%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 7.75, CME has a dividend in line with its industry peers.
CME's Dividend Yield is rather good when compared to the S&P500 average which is at 2.34.
Industry RankSector Rank
Dividend Yield 3.85%

5.2 History

The dividend of CME is nicely growing with an annual growth rate of 16.00%!
CME has been paying a dividend for at least 10 years, so it has a reliable track record.
CME has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)16%
Div Incr Years11
Div Non Decr Years11
CME Yearly Dividends per shareCME Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8 10

5.3 Sustainability

CME pays out 106.75% of its income as dividend. This is not a sustainable payout ratio.
The dividend of CME is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP106.75%
EPS Next 2Y6.97%
EPS Next 3Y7.22%
CME Yearly Income VS Free CF VS DividendCME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B
CME Dividend Payout.CME Dividend Payout, showing the Payout Ratio.CME Dividend Payout.PayoutRetained Earnings

More info and screens

CME GROUP INC

NASDAQ:CME (7/17/2025, 8:13:08 PM)

After market: 277.82 0 (0%)

277.82

+0.29 (+0.1%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)04-23 2025-04-23/bmo
Earnings (Next)07-23 2025-07-23/bmo
Inst Owners91.38%
Inst Owner Change0%
Ins Owners0.24%
Ins Owner Change-1.63%
Market Cap100.12B
Analysts70
Price Target282.95 (1.85%)
Short Float %1.46%
Short Ratio2.21
Dividend
Industry RankSector Rank
Dividend Yield 3.85%
Yearly Dividend9.97
Dividend Growth(5Y)16%
DP106.75%
Div Incr Years11
Div Non Decr Years11
Ex-Date06-09 2025-06-09 (1.25)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.38%
Min EPS beat(2)-1.28%
Max EPS beat(2)2.05%
EPS beat(4)2
Avg EPS beat(4)0.19%
Min EPS beat(4)-1.28%
Max EPS beat(4)2.05%
EPS beat(8)6
Avg EPS beat(8)1.04%
EPS beat(12)10
Avg EPS beat(12)1.02%
EPS beat(16)14
Avg EPS beat(16)1.22%
Revenue beat(2)0
Avg Revenue beat(2)-1.14%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)-0.57%
Revenue beat(4)0
Avg Revenue beat(4)-1%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)-0.57%
Revenue beat(8)1
Avg Revenue beat(8)-0.7%
Revenue beat(12)5
Avg Revenue beat(12)13.84%
Revenue beat(16)9
Avg Revenue beat(16)11.79%
PT rev (1m)0.19%
PT rev (3m)6.04%
EPS NQ rev (1m)-0.86%
EPS NQ rev (3m)7.3%
EPS NY rev (1m)-0.42%
EPS NY rev (3m)4.87%
Revenue NQ rev (1m)-0.81%
Revenue NQ rev (3m)4.93%
Revenue NY rev (1m)-0.52%
Revenue NY rev (3m)1.42%
Valuation
Industry RankSector Rank
PE 26.31
Fwd PE 23.66
P/S 9.83
P/FCF 26.17
P/OCF 25.58
P/B 3.7
P/tB N/A
EV/EBITDA 12.25
EPS(TTM)10.56
EY3.8%
EPS(NY)11.74
Fwd EY4.23%
FCF(TTM)10.62
FCFY3.82%
OCF(TTM)10.86
OCFY3.91%
SpS28.26
BVpS75.01
TBVpS-9.48
PEG (NY)2.69
PEG (5Y)3.07
Profitability
Industry RankSector Rank
ROA 2.27%
ROE 13.25%
ROCE 21.92%
ROIC 17.02%
ROICexc 17.76%
ROICexgc 139.44%
OM 78.35%
PM (TTM) 35.16%
GM N/A
FCFM 37.57%
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
ROICexc(3y)17.24%
ROICexc(5y)12.98%
ROICexgc(3y)263.94%
ROICexgc(5y)202.43%
ROCE(3y)20.37%
ROCE(5y)15.39%
ROICexcg growth 3Y53.64%
ROICexcg growth 5Y25.03%
ROICexc growth 3Y41.34%
ROICexc growth 5Y22.06%
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 0.91
Debt/EBITDA 0.42
Cap/Depr 26.47%
Cap/Sales 0.87%
Interest Coverage 61.44
Cash Conversion 47.08%
Profit Quality 106.83%
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z 0.75
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)29.97%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.86%
Profit Quality(3y)106.99%
Profit Quality(5y)105.5%
High Growth Momentum
Growth
EPS 1Y (TTM)12.1%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%12%
EPS Next Y9.8%
EPS Next 2Y6.97%
EPS Next 3Y7.22%
EPS Next 5Y7.08%
Revenue 1Y (TTM)-4.04%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%10.38%
Revenue Next Year7.77%
Revenue Next 2Y5.91%
Revenue Next 3Y5.91%
Revenue Next 5Y4.32%
EBIT growth 1Y-5.79%
EBIT growth 3Y39.48%
EBIT growth 5Y19.95%
EBIT Next Year12.83%
EBIT Next 3Y8.86%
EBIT Next 5Y7.1%
FCF growth 1Y24.31%
FCF growth 3Y16.49%
FCF growth 5Y8.18%
OCF growth 1Y23.9%
OCF growth 3Y15.38%
OCF growth 5Y6.67%